IRIS
DE ANGELIS, CARMINE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.158
EU - Europa 635
AS - Asia 519
AF - Africa 20
SA - Sud America 1
Totale 2.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.130
IT - Italia 353
SG - Singapore 321
CN - Cina 119
NL - Olanda 80
DE - Germania 77
GB - Regno Unito 30
IE - Irlanda 29
CA - Canada 26
VN - Vietnam 26
FI - Finlandia 22
CI - Costa d'Avorio 20
IN - India 19
JP - Giappone 12
FR - Francia 9
PK - Pakistan 6
UA - Ucraina 6
ES - Italia 5
HK - Hong Kong 5
RU - Federazione Russa 5
SE - Svezia 4
BD - Bangladesh 3
AT - Austria 2
DK - Danimarca 2
GR - Grecia 2
ID - Indonesia 2
MY - Malesia 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BE - Belgio 1
BY - Bielorussia 1
BZ - Belize 1
LI - Liechtenstein 1
LT - Lituania 1
MC - Monaco 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
VE - Venezuela 1
Totale 2.333
Salva come PNG Salva come JPEG
Città #
Singapore 272
Chandler 189
Santa Clara 100
Amsterdam 77
Naples 67
Millbury 65
Ashburn 54
Lawrence 46
Des Moines 38
Beijing 34
Napoli 34
Dearborn 30
Boston 27
Dong Ket 26
Milan 20
Wilmington 20
Princeton 17
Nanjing 16
Ottawa 15
Pune 13
Seattle 12
Kagoya 10
Rome 10
London 9
Lappeenranta 7
Pomigliano d'Arco 7
Casoria 6
Fairfield 6
Formia 6
Hebei 6
Jacksonville 6
Krefeld 6
Nuremberg 6
Campobasso 5
Dublin 5
Hong Kong 5
Redwood City 5
Toronto 5
Wuhan 5
Boardman 4
Edinburgh 4
Hefei 4
Houston 4
Jiaxing 4
Nanchang 4
Palermo 4
Portici 4
Sant'Agnello 4
Bad Durrheim 3
Dhaka 3
Giugliano In Campania 3
Granada 3
Guangzhou 3
Kronberg 3
Lahore 3
Luco dei Marsi 3
Menlo Park 3
Munich 3
Salerno 3
Shanghai 3
Woodbridge 3
Bari 2
Bologna 2
Braga 2
Carpi 2
Castelli Calepio 2
Castelnuovo del Garda 2
Changsha 2
Chengdu 2
Ercolano 2
Helsinki 2
Klaten 2
Kuala Lumpur 2
Kunming 2
Lomazzo 2
Marcianise 2
Norwalk 2
Padova 2
Redmond 2
Sennori 2
Somma Vesuviana 2
Teano 2
Vercelli 2
Villaricca 2
Washington 2
Angri 1
Athens 1
Augusta 1
Avellino 1
Belize City 1
Benfleet 1
Benxi 1
Brussels 1
Cambridge 1
Casalnuovo 1
Caserta 1
Castelfranco 1
Castellammare Di Stabia 1
Cava De' Tirreni 1
Changchun 1
Totale 1.425
Salva come PNG Salva come JPEG
Nome #
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 92
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 65
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 53
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 52
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 52
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 51
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 51
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 50
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 49
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 48
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 47
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 47
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 44
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 43
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 41
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 40
Tumor characteristics and prognosis in familial breast cancer 40
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 40
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study 39
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 38
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 37
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 37
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 37
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 36
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer 36
Brca1/2 ngs somatic testing in clinical practice: a short report 35
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 34
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 33
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 31
GMO-Gestione Malattie Oncologiche in Regione Campania. 31
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer 31
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer 31
Prevalence of Sarcopenia in Women with Breast Cancer 30
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy 29
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer 28
Triple-negative breast cancers: Biomarkers and outcomes 28
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance 28
Molecular mechanisms of endocrine resistance 28
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 27
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. 27
Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis 27
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer 26
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 25
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance 25
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 24
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. 24
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance 24
HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer 23
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer 22
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 21
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 21
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance 21
The changing role of ER in endocrine resistance 21
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 21
Resistance to Anti-HER2 Therapies in Breast Cancer 21
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer 21
PTK6 regulates growth and survival of endocrine therapyresistant ER+ breast cancer cells 20
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer 20
How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy 19
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 18
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients 18
Towards personalized treatment for early stage HER2-positive breast cancer 18
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 17
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 16
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 16
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 16
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy 16
Neratinib in HER2-Positive Breast Cancer Patients 16
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 16
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 15
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer 15
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer 15
Ribociclib in newly diagnosed hepatitis B infection: A case report 14
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 14
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 14
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer 14
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer 14
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models 13
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials 12
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 12
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 12
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic 12
Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment 12
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 11
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition 11
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 10
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 10
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer 10
Editorial: Molecular predictive pathology in gynecologic malignancies 10
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 10
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. 9
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 8
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 7
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 7
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 6
Totale 2.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202072 0 0 0 0 0 0 10 12 6 17 26 1
2020/2021155 2 0 11 14 13 13 13 6 30 9 12 32
2021/2022410 7 1 61 1 6 14 11 14 37 32 95 131
2022/2023568 66 36 21 30 57 56 15 52 69 96 53 17
2023/2024478 15 70 59 28 22 53 10 41 17 19 97 47
2024/2025592 136 167 7 71 58 145 8 0 0 0 0 0
Totale 2.506